[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 20 of about 20
1. Quach H, Januszewicz H, Westerman D: Complete remission of hairy cell leukemia variant (HCL-v) complicated by red cell aplasia post treatment with rituximab. Haematologica; 2005 Nov;90 Suppl:ECR26
Hazardous Substances Data Bank. PREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete remission of hairy cell leukemia variant (HCL-v) complicated by red cell aplasia post treatment with rituximab.
  • Hairy cell leukemia variant (HCL-v) is a rare form of a chronic B-cell lymphoproliferative disorder.
  • Unlike typical hairy cell leukemia (HCL) where the complete response (CR) rate to 2-chlorodeoxyadenosine and 2'-deoxycoformycin can approach about 90%, in HCL-v CR is rare and partial response (PR) occurs in approximately 50% with these agents.
  • Rituximab treatment in relapsed or refractory HCL results in a CR of 13% to 53%, but its use in HCL-v has not been reported in the literature to our knowledge.
  • We describe a patient with HCL-v, whose course was previously complicated by pure red cell aplasia who achieved CR after treatment with rituximab.
  • We also briefly review outcomes of treatments used in HCL-v reported in the current literature.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Leukemia, Hairy Cell / drug therapy. Neoplasms, Second Primary / drug therapy. Red-Cell Aplasia, Pure / etiology
  • [MeSH-minor] 2-Chloroadenosine / administration & dosage. 2-Chloroadenosine / analogs & derivatives. Aged. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Blood Transfusion. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Deoxyadenosines / administration & dosage. Disease Progression. Drug Resistance, Neoplasm. Fatal Outcome. Humans. Interferon-alpha / administration & dosage. Male. Prednisolone / administration & dosage. Recurrence. Remission Induction. Rituximab. Splenectomy. Urinary Bladder Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Hairy Cell Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16266917.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Deoxyadenosines; 0 / Interferon-alpha; 115044-75-2 / 2-chloro-3'-deoxyadenosine; 146-77-0 / 2-Chloroadenosine; 4F4X42SYQ6 / Rituximab; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


2. Palomera L, Domingo JM, Sola C, Azaceta G, Calvo MT, Gutierrez M: Cladribine (2-chlorodeoxyadenosine) therapy in hairy cell leukemia variant. A report of three cases. Haematologica; 2002 Jan;87(1):107-8
Hazardous Substances Data Bank. CLADRIBINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cladribine (2-chlorodeoxyadenosine) therapy in hairy cell leukemia variant. A report of three cases.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Cladribine / therapeutic use. Leukemia, Hairy Cell / drug therapy
  • [MeSH-minor] Aged. Combined Modality Therapy. Drug Evaluation. Female. Follow-Up Studies. Humans. Interferon-alpha / therapeutic use. Male. Middle Aged. Remission Induction. Salvage Therapy. Splenectomy. Treatment Outcome

  • Genetic Alliance. consumer health - Hairy Cell Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11801472.001).
  • [ISSN] 0390-6078
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Interferon-alpha; 47M74X9YT5 / Cladribine
  •  go-up   go-down


3. Arons E, Suntum T, Stetler-Stevenson M, Kreitman RJ: VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy. Blood; 2009 Nov 19;114(21):4687-95
Hazardous Substances Data Bank. CLADRIBINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy.
  • Hairy cell leukemia variant (HCLv) presents with high disease burden, lack of typical antigens like CD25, and poor response to standard treatments like cladribine.
  • Occasionally, patients with classic HCL respond poorly.
  • Clinical and molecular features of HCL and HCLv has not been compared.
  • Rearrangements expressing immunoglobulin VH chain were sequenced, including 22 from 20 patients with HCLv and 63 from 62 patients with classic HCL.
  • VH4-34, a gene commonly used in autoimmune disorders, was observed in 8 (40%) HCLv and 6 (10%) classic (P = .004) HCL patients.
  • VH4-34(+) patients had greater white blood cell counts at diagnosis (P = .002), lower response rate (P < .001) and progression-free survival (P = .007) after initial cladribine, and shorter overall survival from diagnosis (P < .001).
  • VH4-34(+) HCL is an important disorder that only partly overlaps with the previously described HCLv.
  • Response to initial single-agent cladribine therapy is suboptimal; these patients should be considered for alternative approaches, including antibody-related therapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cladribine / therapeutic use. Complementarity Determining Regions / genetics. Immunoglobulin Heavy Chains / genetics. Leukemia, Hairy Cell / drug therapy. Leukemia, Hairy Cell / genetics

  • Genetic Alliance. consumer health - Hairy Cell Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Haematologica. 2005 Nov;90 Suppl:ECR26 [16266917.001]
  • [Cites] Cancer. 2005 Dec 1;104(11):2442-8 [16245328.001]
  • [Cites] Br J Haematol. 2006 Jun;133(5):504-12 [16681637.001]
  • [Cites] Cancer. 2007 Nov 15;110(10):2240-7 [17886250.001]
  • [Cites] Clin Lymphoma Myeloma. 2007 Nov;7(9):573-9 [18186965.001]
  • [Cites] J Clin Pathol. 2008 Mar;61(3):377-81 [17601964.001]
  • [Cites] Blood. 2006 Jun 15;107(12):4658-62 [16497968.001]
  • [Cites] Hematol Oncol Clin North Am. 2006 Oct;20(5):1051-63 [16990106.001]
  • [Cites] Haematologica. 2007 May;92(5):690-3 [17488696.001]
  • [Cites] Leukemia. 2008 Mar;22(3):487-95 [18094718.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2008 Mar;16(2):135-9 [18227730.001]
  • [Cites] Haematologica. 2008 May;93(5):697-705 [18387977.001]
  • [Cites] Blood. 1995 Oct 15;86(8):3072-82 [7579401.001]
  • [Cites] Leuk Lymphoma. 1995 May;17(5-6):435-41 [7549834.001]
  • [Cites] Br J Haematol. 1996 May;93(2):409-11 [8639440.001]
  • [Cites] Blood. 1996 Apr 1;87(7):2846-52 [8639903.001]
  • [Cites] Clin Exp Immunol. 1996 Jul;105(1):183-90 [8697629.001]
  • [Cites] Clin Exp Immunol. 1997 Apr;108(1):151-9 [9097924.001]
  • [Cites] Am J Pathol. 1999 Dec;155(6):2077-86 [10595937.001]
  • [Cites] J Immunol. 2000 Mar 1;164(5):2782-9 [10679121.001]
  • [Cites] Leuk Lymphoma. 1999 Oct;35(3-4):347-54 [10706459.001]
  • [Cites] Neurology. 2000 Mar 28;54(6):1227-32 [10746589.001]
  • [Cites] Clin Immunol. 2001 Feb;98(2):258-63 [11161983.001]
  • [Cites] Leukemia. 2001 Jan;15(1):184-6 [11243388.001]
  • [Cites] N Engl J Med. 2001 Jul 26;345(4):241-7 [11474661.001]
  • [Cites] Blood. 2001 Aug 15;98(4):1174-81 [11493467.001]
  • [Cites] J Rheumatol. 2002 Oct;29(10):2114-21 [12375320.001]
  • [Cites] Leukemia. 2003 Jan;17(1):45-51 [12529659.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):891-6 [12610190.001]
  • [Cites] Best Pract Res Clin Haematol. 2003 Mar;16(1):41-56 [12670464.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] Leukemia. 2004 Oct;18(10):1729-32 [15356640.001]
  • [Cites] Leuk Res. 1980;4(6):547-59 [7206776.001]
  • [Cites] Biochem Biophys Res Commun. 1983 Jan 27;110(2):424-31 [6601483.001]
  • [Cites] Br J Haematol. 1989 May;72(1):9-15 [2472169.001]
  • [Cites] Blood. 1990 Jul 1;76(1):157-62 [2364167.001]
  • [Cites] Int Immunol. 1989;1(4):362-6 [2562243.001]
  • [Cites] Blood. 1991 Nov 1;78(9):2372-86 [1657249.001]
  • [Cites] J Immunol. 1992 Oct 1;149(7):2337-44 [1382098.001]
  • [Cites] Br J Haematol. 1992 Nov;82(3):547-54 [1283078.001]
  • [Cites] J Exp Med. 1993 Feb 1;177(2):409-18 [8426111.001]
  • [Cites] Ann Intern Med. 1993 Aug 15;119(4):278-83 [8101069.001]
  • [Cites] Br J Haematol. 1993 Jun;84(2):242-9 [8398825.001]
  • [Cites] J Immunol. 1993 Nov 1;151(9):5011-21 [7691963.001]
  • [Cites] Blood. 1993 Nov 15;82(10):3103-12 [7693035.001]
  • [Cites] Blood. 1994 May 15;83(10):2952-61 [8180391.001]
  • [Cites] Eur J Immunol. 1994 Dec;24(12):2941-9 [7805720.001]
  • [Cites] Leuk Lymphoma. 1994;14 Suppl 1:121-5 [7820043.001]
  • [Cites] Leuk Lymphoma. 1994;14 Suppl 1:79-83 [7820058.001]
  • [Cites] J Clin Oncol. 1995 Apr;13(4):974-82 [7707126.001]
  • [Cites] J Immunol. 1995 Jun 15;154(12):6406-20 [7759877.001]
  • [Cites] J Clin Invest. 1997 May 15;99(10):2488-501 [9153293.001]
  • [Cites] Leuk Lymphoma. 1997 Apr;25(3-4):381-5 [9168448.001]
  • [Cites] Clin Immunol Immunopathol. 1997 Sep;84(3):283-9 [9281387.001]
  • [Cites] Br J Haematol. 1998 Apr;101(1):171-8 [9576198.001]
  • [Cites] Blood. 1998 Sep 15;92(6):1918-26 [9731048.001]
  • [Cites] Hum Pathol. 1999 Mar;30(3):306-12 [10088550.001]
  • [Cites] J Rheumatol. 1999 Aug;26(8):1727-33 [10451069.001]
  • [Cites] Blood. 1999 Sep 15;94(6):1848-54 [10477713.001]
  • [Cites] J Immunol. 1999 Nov 1;163(9):5133-44 [10528220.001]
  • [Cites] Haematologica. 2004 Nov;89(11):ECR41 [15533846.001]
  • [Cites] Leuk Res. 2005 Feb;29(2):153-8 [15607363.001]
  • [Cites] Int J Hematol. 2004 Dec;80(5):432-4 [15646655.001]
  • [Cites] Am J Clin Pathol. 2005 Jan;123(1):132-8 [15762289.001]
  • [Cites] Blood. 2005 Jul 1;106(1):241-6 [15761021.001]
  • [Cites] Haematologica. 2005 Jul;90(7):906-13 [15996928.001]
  • [Cites] Leuk Lymphoma. 2005 Aug;46(8):1229-32 [16085567.001]
  • [Cites] J Clin Oncol. 2005 Sep 20;23(27):6719-29 [16061911.001]
  • [Cites] Am J Clin Pathol. 2005 Sep;124(3):414-20 [16191510.001]
  • [CommentIn] Blood. 2009 Nov 19;114(21):4610-1 [19965713.001]
  • (PMID = 19745070.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Complementarity Determining Regions; 0 / Immunoglobulin Heavy Chains; 47M74X9YT5 / Cladribine
  • [Other-IDs] NLM/ PMC2780305
  •  go-up   go-down


Advertisement
4. Goldaniga M, Guffanti A, Gianelli U, Magni M, Lambertenghi Deliliers G, Baldini L: Clinical and molecular complete remission in a case of variant hairy cell leukemia treated with DHAP followed by high-dose chemotherapy plus rituximab. Haematologica; 2004 Nov;89(11):ECR41
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and molecular complete remission in a case of variant hairy cell leukemia treated with DHAP followed by high-dose chemotherapy plus rituximab.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Hairy Cell / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Cisplatin / administration & dosage. Cisplatin / therapeutic use. Combined Modality Therapy. Cytarabine / administration & dosage. Cytarabine / therapeutic use. Dexamethasone / administration & dosage. Dexamethasone / therapeutic use. Humans. Male. Middle Aged. Remission Induction. Rituximab. Stem Cell Transplantation

  • Genetic Alliance. consumer health - Hairy Cell Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15533846.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine; 4F4X42SYQ6 / Rituximab; 7S5I7G3JQL / Dexamethasone; Q20Q21Q62J / Cisplatin; DHAP protocol
  •  go-up   go-down


5. Sasaki M, Sugimoto K, Mori T, Karasawa K, Oshimi K: Effective treatment of a refractory hairy cell leukemia variant with splenic pre-irradiation and alemtuzumab. Acta Haematol; 2008;119(1):48-53
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effective treatment of a refractory hairy cell leukemia variant with splenic pre-irradiation and alemtuzumab.
  • A 72-year-old Japanese man presented with 43.1 x 10(9)/l hairy cells and apparent splenomegaly.
  • The leukemia cells had unevenly distributed microvilli and round nuclei with dense chromatin and one or two clear nucleoli, lacked CD25 expression and were negative for tartrate-resistant acid phosphatase.
  • The case was diagnosed as hairy cell leukemia variant (HCLv) and proved refractory to various chemotherapies, including cladribine, pentostatin, interferon-alpha, CHOP and rituximab.
  • Pretreatment with 22.5 Gy to the spleen reduced the spleen size from 12 to 4 cm below the left costal margin, and the number of circulating leukemic cells decreased from 229.0 to 63.6 x 10(9)/l.
  • In vitro treatment with alemtuzumab confirmed the cytotoxic effect against the patient's leukemic cells in the presence of complement.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Antineoplastic Agents / therapeutic use. Leukemia, Hairy Cell / drug therapy. Leukemia, Hairy Cell / radiotherapy. Spleen / radiation effects
  • [MeSH-minor] Aged. Antibodies, Monoclonal, Humanized. Antigens, CD / immunology. Antigens, Neoplasm / immunology. Combined Modality Therapy. Fluorescent Antibody Technique. Glycoproteins / immunology. Humans. Immunophenotyping. Male

  • Genetic Alliance. consumer health - Hairy Cell Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2008 S. Karger AG, Basel
  • (PMID = 18259114.001).
  • [ISSN] 1421-9662
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antigens, CD; 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; 0 / CD52 antigen; 0 / Glycoproteins; 3A189DH42V / alemtuzumab
  •  go-up   go-down


6. Narat S, Gandla J, Dogan A, Mehta A: Successful treatment of hairy cell leukemia variant with rituximab. Leuk Lymphoma; 2005 Aug;46(8):1229-32
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of hairy cell leukemia variant with rituximab.
  • Hairy cell leukemia (HCL) variant is a rare low-grade B-cell disorder affecting the elderly or middle-aged population with features intermediate between those of HCL and prolymphocytic leukemia.
  • Unlike HCL, it is resistant to most conventional treatment.
  • We report a case of a 53-year-old man who had refractory thrombocytopenia and lymphocytosis for 8 years.
  • Investigations and analysis of spleen and bone marrow revealed a diagnosis of HCL variant.
  • He opted for treatment with rituximab, a chimeric monoclonal antibody targeting CD 20.
  • There was complete recovery of his full blood count and a bone marrow biopsy performed 3 months post-treatment showed complete remission.
  • This is, to our knowledge, the first reported patient with HCL variant for whom treatment with rituximab was successful, and this treatment needs further investigation.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Leukemia, Hairy Cell / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Cell Count. Humans. Male. Middle Aged. Remission Induction / methods. Rituximab. Treatment Outcome

  • Genetic Alliance. consumer health - Hairy Cell Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16085567.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


7. Nagai T, Izumi T, Noborio K, Takatoku M, Ohtsuki T, Machii T, Komatsu N, Ozawa K: [Successful treatment of hairy cell leukemia prolymphocytic variant with 2'-deoxycoformycin]. Rinsho Ketsueki; 2002 Jul;43(7):583-5
Hazardous Substances Data Bank. PENTOSTATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Successful treatment of hairy cell leukemia prolymphocytic variant with 2'-deoxycoformycin].
  • The hairy cell leukemia prolymphocytic variant, a subtype of hairy cell leukemia, is an extremely rare disease, especially in Japan.
  • We report a case in which treatment with 2'-deoxycoformycin (DCF) improved the clinical features of the disease.
  • Following the start of this treatment, the leukemia cell count rapidly decreased and the platelet count simultaneously increased.
  • More clinical studies are needed to confirm the therapeutic value of DCF.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Leukemia, Hairy Cell / drug therapy. Leukemia, Prolymphocytic / drug therapy. Pentostatin / therapeutic use

  • Genetic Alliance. consumer health - Hairy Cell Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12229130.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 395575MZO7 / Pentostatin
  •  go-up   go-down


8. Ng JP, Nolan B, Chan-Lam D, Coup AJ, McKenna D: Successful treatment of aplastic variant of hairy-cell leukaemia with deoxycoformycin. Hematology; 2002 Aug;7(4):259-62
Hazardous Substances Data Bank. PENTOSTATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of aplastic variant of hairy-cell leukaemia with deoxycoformycin.
  • The case of a patient with the aplastic variant of hairy cell leukaemia, successfully treated with the drug Deoxycoformycin(Pentostatin), is presented.
  • It is very important to be aware of this rare variant of a rare disease so that the right treatment can be offered.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Bone Marrow / pathology. Diagnostic Errors. Leukemia, Hairy Cell / drug therapy. Pentostatin / therapeutic use
  • [MeSH-minor] Anemia, Aplastic / diagnosis. Female. Humans. Middle Aged. Pancytopenia / etiology. Remission Induction. Splenomegaly / etiology. Sweating

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14972788.001).
  • [ISSN] 1024-5332
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 395575MZO7 / Pentostatin
  •  go-up   go-down


9. Telek B, Batár P, Udvardy M: [Successful alemtuzumab treatment of a patient with atypical hairy cell leukaemia variant]. Orv Hetil; 2007 Sep 23;148(38):1805-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Successful alemtuzumab treatment of a patient with atypical hairy cell leukaemia variant].
  • Although hairy cell leukaemia and hairy cell leukaemia variant are characterized by much alike clinical features, these two diseases are disparate in nature and treatment.
  • While hairy cell leukaemia responds quite well to 2-chlorodeoxyadenosine (cladribine) treatment, hairy cell leukaemia variant has much worse response rate and has no effective treatment option yet.
  • With other treatment modalities, including monoclonal antibody treatment, we have less experience.
  • Alemtuzumab (Campath-1H, MabCampath) treatment has been reported in a case with hairy cell leukaemia in relaps while there is no data with alemtuzumab therapy in the treatment of hairy cell leukaemia variant.
  • The authors present their case of a 58 year-old male who has been diagnosed with hairy cell leukaemia variant upon clinical findings and lymphocyte phenotyping.
  • Alemtuzumab treatment was started (3 x 30 mg/week s.c. for 12 weeks).
  • After 8 weeks of treatment haematologic remission was achieved; flow cytometry has revealed only 1.5% malignant cells.
  • Alemtuzumab treatment can be favourable in those cases of hairy cell leukaemia and hairy cell leukaemia variant which is dominated mainly by bone marrow infiltration and present no lymphadenomegaly or splenomegaly.
  • In our case the p53 mutation had no influence on the outcome of alemtuzumab treatment.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Antineoplastic Agents / therapeutic use. Leukemia, Hairy Cell / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Antigens, CD / blood. Biomarkers, Tumor / blood. Drug Administration Schedule. Humans. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17872336.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antigens, CD; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 3A189DH42V / alemtuzumab
  •  go-up   go-down


10. Matutes E, Wotherspoon A, Catovsky D: The variant form of hairy-cell leukaemia. Best Pract Res Clin Haematol; 2003 Mar;16(1):41-56
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The variant form of hairy-cell leukaemia.
  • Hairy-cell leukaemia-variant (HCL-variant) is a rare B-cell disorder which accounts for 10% of HCL cases.
  • The circulating cells have a morphology intermediate between prolymphocytes and hairy cells.
  • The immunophenotype shows a mature B-cell phenotype with expression of the B-cell antigens CD11c and CD103-but unlike typical HCL the cells are CD25- and HC2-negative.
  • The histology of bone marrow and spleen shows a pattern of infiltration similar to that in HCL.
  • Splenectomy results in long-lasting partial responses in over two-thirds of the patients and is a good palliative treatment.
  • Despite the lack of response to most therapies, the clinical course of HCL-variant is chronic.
  • Transformation to large cell is seen in 6% of patients.
  • The inferior survival in HCL-variant compared with typical HCL cases may reflect the chemotherapy resistance.
  • [MeSH-major] Leukemia, Hairy Cell / pathology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. B-Lymphocytes / immunology. B-Lymphocytes / pathology. Cladribine / therapeutic use. Diagnosis, Differential. Humans. Immunophenotyping. Interferon-alpha / therapeutic use. Male. Survival Analysis

  • Hazardous Substances Data Bank. CLADRIBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12670464.001).
  • [ISSN] 1521-6926
  • [Journal-full-title] Best practice & research. Clinical haematology
  • [ISO-abbreviation] Best Pract Res Clin Haematol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 47M74X9YT5 / Cladribine
  • [Number-of-references] 40
  •  go-up   go-down


11. Hadzi-Pecova L, Stojanovik A, Petrusevska G, Panovska I: Rituximab in the treatment of the variant of hairy cell leukaemia: a case report. Prilozi; 2008 Dec;29(2):355-60
Hazardous Substances Data Bank. CLADRIBINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab in the treatment of the variant of hairy cell leukaemia: a case report.
  • Hairy cell leukaemia (HCL) is an uncommon, low-grade B-cell lymphoproliferative disorder.
  • HCL-variant describes an entity of HCL that is important from the point of view of requiring differential diagnosis from HCL, and for requiring careful consideration of the treatment approach.
  • HCL-variant differs from the classic form with respect to the lack of monocytopaenia, its elevated WBC and unique morphology and immunophenotype.
  • Indeed, there is currently no adequate standard treatment for this condition - HCL-variant is generally resistant to interferon-alpha, and complete remission is rarely achieved with either pentostatin or cladribine.
  • Based on her blood morphology, bone marrow and spleen histology, immunophenotype and clinical characteristics, the patient was diagnosed as having HCL-variant, with blastoid variant transformation.
  • One month later the blood counts deteriorated, she developed peripheral and abdominal lymphadenopathy and had poor performance status.
  • Our experience from this case suggests that rituximab is a promising therapy for patients with HCL-variant, particularly when combined with cladribine.
  • However, further clinical study is required before rituximab can be considered as a front-line therapy for this form of malignancy.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19259059.001).
  • [ISSN] 0351-3254
  • [Journal-full-title] Prilozi
  • [ISO-abbreviation] Prilozi
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 47M74X9YT5 / Cladribine; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


12. Johnson SA: Use of fludarabine in the treatment of mantle cell lymphoma, Waldenström's macroglobulinemia and other uncommon B- and T-cell lymphoid malignancies. Hematol J; 2004;5 Suppl 1:S50-61
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of fludarabine in the treatment of mantle cell lymphoma, Waldenström's macroglobulinemia and other uncommon B- and T-cell lymphoid malignancies.
  • After initial efforts using fludarabine as a single agent in the treatment of acute leukemia, its activity at lower and safer doses was demonstrated in chronic lymphocytic leukemia (CLL) patients who were refractory or had relapsed from traditional chemotherapies, representing a highly effective therapy for this condition.
  • Fludarabine was also rapidly shown to be beneficial as first-line therapy in CLL.
  • There is now considerable evidence that fludarabine is an effective agent in non-Hodgkin's lymphoma and in combination therapy for acute myeloid leukemia.
  • The actions of fludarabine are not restricted to these settings and its potential role in the treatment of a range of uncommon T- and B-cell lymphoid malignancies is slowly emerging.
  • This review will focus on the characteristics and treatment options for two B-cell disorders, mantle cell lymphoma and Waldenström's macroglobulinemia, with emphasis on the clinical activity of fludarabine.
  • These include B-cell neoplasms such as the CLL variant prolymphocytic leukemia, hairy cell leukemia and mucosa-associated lymphoid tissue-derived lymphomas; the T-cell disorders cutaneous T-cell lymphoma, angioimmunoblastic lymphadenopathy and other rarer T-cell diseases; and aggressive variants of non-Hodgkin's lymphoma including Richter's syndrome.

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15079153.001).
  • [ISSN] 1466-4860
  • [Journal-full-title] The hematology journal : the official journal of the European Haematology Association
  • [ISO-abbreviation] Hematol. J.
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  • [Number-of-references] 108
  •  go-up   go-down


13. Miyazaki M, Taguchi A, Sakuragi S, Mitani N, Matsuda K, Shinohara K: [Hairy cell leukemia, Japanese variant, successfully treated with cladribine]. Rinsho Ketsueki; 2004 May;45(5):405-7
Hazardous Substances Data Bank. CLADRIBINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hairy cell leukemia, Japanese variant, successfully treated with cladribine].
  • Abnormal lymphocytes had cytoplasmic hairy projections and were negative for tartrate-resistant acid phosphatase staining.
  • The patient was diagnosed as having hairy cell leukemia, Japanese variant.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cladribine / therapeutic use. Leukemia, Hairy Cell / drug therapy

  • Genetic Alliance. consumer health - Hairy Cell Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15199752.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 47M74X9YT5 / Cladribine
  •  go-up   go-down


14. Kristinsson SY, Vidarsson B, Agnarsson BA, Haraldsdottir V, Olafsson O, Johannesson GM, Eyjolfsson GI, Bjornsdottir J, Onundarson PT, Reykdal S: Epidemiology of hairy cell leukemia in Iceland. Hematol J; 2002;3(3):145-7
Genetic Alliance. consumer health - Hairy Cell Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiology of hairy cell leukemia in Iceland.
  • INTRODUCTION: Hairy cell leukemia (HCL) is a rare B-cell lymphoproliferative disorder.
  • This is the first study in which all cases diagnosed nationwide over a long period of time in a well defined population are analysed.
  • We report the epidemiology of all HCL patients in Iceland, their clinical characteristics, treatment and follow-up.
  • PATIENTS AND METHODS: : All patients diagnosed with HCL in Iceland over a 20 year period, were included in this study.
  • RESULTS: Sixteen patients, 13 males and three females were diagnosed with HCL in Iceland from 1981-2000, giving a mean incidence of 4.7/million/year (95% CI: 2.7-7.6) in the population 20 years and older.
  • Eleven patients were treated with a purine analogue, 10 of whom achieved CR.
  • One patient had a variant of HCL and did not respond to any therapy and one patient died of sepsis before any chemotherapy could be given.
  • Six patients with HCL have died, one from complications of HCL.
  • Three patients developed a second malignancy (19%).
  • CONCLUSIONS: The mean incidence of HCL in Iceland is 4.7/million/year.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12111650.001).
  • [ISSN] 1466-4860
  • [Journal-full-title] The hematology journal : the official journal of the European Haematology Association
  • [ISO-abbreviation] Hematol. J.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


15. Makita M, Nakamura K, Kono A: [Successful rituximab treatment in a patient with refractory hairy cell leukemia-Japanese variant and suffering from acute respiratory distress]. Rinsho Ketsueki; 2005 Nov;46(11):1196-201
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Successful rituximab treatment in a patient with refractory hairy cell leukemia-Japanese variant and suffering from acute respiratory distress].
  • A 69-year-old man was referred to our hospital because of thrombocytopenia and was diagnosed as having hairy cell leukemia-Japanese variant (HCL-Jv) in December 2000.
  • In addition, the number of hairy cells (HCs) in his peripheral blood (PB) began gradually to increase.
  • He received treatment with interferon-alpha and cladribine, but he failed to respond completely to these treatments.
  • His white blood cell count was 123.1 X 10(9)/L with 91% HCs.
  • Radiography and computed tomography of his chest revealed ground-glass opacity in both lungs.
  • After 8 courses of rituximab therapy, the HCs disappeared in his PB and BM, and his pulmonary infiltrates subsided.
  • These results suggest that rituximab may be a very effective treatment for refractory HCL-Jv.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Agents / administration & dosage. Leukemia, Hairy Cell / complications. Leukemia, Hairy Cell / drug therapy. Respiratory Distress Syndrome, Adult / etiology
  • [MeSH-minor] Aged. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Leukemic Infiltration / complications. Leukemic Infiltration / drug therapy. Lung / pathology. Male. Melphalan / administration & dosage. Rituximab

  • Genetic Alliance. consumer health - Hairy Cell Leukemia.
  • Hazardous Substances Data Bank. MELPHALAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16440803.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab; Q41OR9510P / Melphalan
  •  go-up   go-down


16. Imamura T, Ohtsuka E, Ogata M, Oka F, Kashima K, Kikuchi H, Nasu M: Successful induction of long-term remission using rituximab in a patient with refractory hairy cell leukemia-Japanese variant. Int J Hematol; 2004 Dec;80(5):432-4
Hazardous Substances Data Bank. PENTOSTATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful induction of long-term remission using rituximab in a patient with refractory hairy cell leukemia-Japanese variant.
  • We report the case of a 76-year-old man with hairy cell leukemia (HCL)-Japanese variant who underwent rituximab therapy.
  • HCL proved refractory to treatment with pentostatin and cladribine, and the number of hairy cells in the peripheral blood continued to increase after splenectomy.
  • The patient was treated with rituximab (375 mg/m2 intravenously weekly for 4 cycles), and hairy cells disappeared from the peripheral blood on the day after the first administration.
  • Complete remission continued for 18 months after treatment.
  • Although they produce high response rates in typical HCL, nucleoside analogs are associated with an inferior clinical response in HCL-Japanese variant, and repetitive administration of these agents increases the risk of serious infections.
  • This encouraging result suggests that rituximab therapy should be considered as salvage therapy for refractory HCL-Japanese variant.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Antibodies, Monoclonal / administration & dosage. Antineoplastic Agents / administration & dosage. Cladribine / administration & dosage. Leukemia, Hairy Cell / drug therapy. Pentostatin / administration & dosage
  • [MeSH-minor] Aged. Antibodies, Monoclonal, Murine-Derived. Drug Therapy, Combination. Humans. Japan. Male. Remission Induction. Rituximab

  • Genetic Alliance. consumer health - Hairy Cell Leukemia.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. CLADRIBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 2001 Dec;115(3):609-11 [11736943.001]
  • [Cites] Rinsho Ketsueki. 1988 Nov;29(11):2029-36 [3070073.001]
  • [Cites] Blood. 1985 Apr;65(4):974-83 [3978236.001]
  • [Cites] Blood. 1986 Aug;68(2):493-7 [3730612.001]
  • [Cites] Ann Oncol. 1994 Jan;5(1):57-64 [7909685.001]
  • [Cites] Blood. 1994 Dec 1;84(11):3828-34 [7949139.001]
  • [Cites] J Clin Oncol. 1998 Sep;16(9):3007-15 [9738569.001]
  • [Cites] Blood. 2003 Aug 1;102(3):810-3 [12663446.001]
  • [Cites] Leuk Res. 1980;4(6):547-59 [7206776.001]
  • [Cites] Int J Hematol. 2002 Dec;76(5):385-93 [12512832.001]
  • [Cites] Leukemia. 1993 Feb;7(2):181-6 [8426471.001]
  • [Cites] N Engl J Med. 1990 Apr 19;322(16):1117-21 [1969613.001]
  • [Cites] J Clin Oncol. 1989 Oct;7(10):1533-8 [2789273.001]
  • [Cites] J Clin Oncol. 1995 Sep;13(9):2431-48 [7666104.001]
  • [Cites] Leukemia. 1996 Aug;10(8):1390-4 [8709650.001]
  • [Cites] Ann Hematol. 2002 Dec;81(12):736-8 [12483372.001]
  • [Cites] Blood. 1958 Jul;13(7):609-30 [13560561.001]
  • [Cites] Br J Haematol. 1997 Oct;99(1):165-7 [9359518.001]
  • [Cites] Lancet Oncol. 2003 Feb;4(2):86-94 [12573350.001]
  • [Cites] J Clin Oncol. 1995 Apr;13(4):974-82 [7707126.001]
  • [Cites] Blood. 2003 Dec 1;102(12):3906-11 [12816862.001]
  • [Cites] Jpn J Clin Oncol. 1992 Dec;22(6):406-10 [1291757.001]
  • [Cites] N Engl J Med. 1971 Feb 18;284(7):357-60 [5275977.001]
  • [Cites] Proc Natl Acad Sci U S A. 1983 Jul;80(14):4522-6 [6192435.001]
  • (PMID = 15646655.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 395575MZO7 / Pentostatin; 47M74X9YT5 / Cladribine; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


17. Machii T, Chou T, Suzuki M, Ohe Y, Katagiri S, Kitano EK, Kitano K, Fujiyama Y, Izumi T, Shimazaki C, Nanba K, Ohashi Y, Kitani T, Cladribine Study Group: Phase II clinical study of cladribine in the treatment of hairy cell leukemia. Int J Hematol; 2005 Oct;82(3):230-5
Hazardous Substances Data Bank. CLADRIBINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II clinical study of cladribine in the treatment of hairy cell leukemia.
  • We conducted a phase II clinical study to evaluate the therapeutic efficacy of cladribine (2-chlorodeoxyadenosine [2-CdA]) in the treatment of Japanese patients with hairy cell leukemia (HCL).
  • Seven patients with classic HCL and 3 with a prolymphocytic HCL variant were administered 2-CdA (0.09 mg/kg per day) by continuous intravenous infusion for 7 days.
  • Seven patients responded to this therapy, with 5 patients achieving a complete response (CR).
  • At treatment initiation, most patients had hematologic impairment as a manifestation of HCL.
  • During the early stage after administration, further hematologic impairment occurred, but subsequent peripheral blood counts gradually recovered as 2-CdA treatment showed antitumor activity.
  • Infections occurred at a high incidence at this time, but all cases could be controlled with appropriate treatment.
  • 2-CdA was surmised to represent a useful therapeutic approach for Japanese patients with HCL.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Cladribine / administration & dosage. Leukemia, Hairy Cell / drug therapy
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Male. Middle Aged. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - Hairy Cell Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 1997 May;11(5):629-32 [9180283.001]
  • [Cites] Leuk Lymphoma. 1994;14 Suppl 1:121-5 [7820043.001]
  • [Cites] Rinsho Ketsueki. 1988 Nov;29(11):2029-36 [3070073.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):1138-42 [9060556.001]
  • [Cites] Blood. 1982 Sep;60(3):571-7 [7104487.001]
  • [Cites] Leukemia. 1992;6 Suppl 2:24-7 [1349662.001]
  • [Cites] Blood. 1992 Mar 1;79(5):1111-20 [1371410.001]
  • [Cites] Jpn J Clin Oncol. 1993 Aug;23(4):250-7 [8411739.001]
  • [Cites] Leuk Res. 1980;4(6):547-59 [7206776.001]
  • [Cites] Leukemia. 1993 Feb;7(2):181-6 [8426471.001]
  • [Cites] N Engl J Med. 1990 Apr 19;322(16):1117-21 [1969613.001]
  • [Cites] Int J Hematol. 2003 Jun;77(5):512-7 [12841391.001]
  • [Cites] Blood. 1998 Sep 15;92(6):1918-26 [9731048.001]
  • [Cites] Lancet. 1992 Oct 17;340(8825):952-6 [1357355.001]
  • [Cites] Ann Hematol. 1999 Mar;78(3):139-44 [10211756.001]
  • [Cites] Nihon Ketsueki Gakkai Zasshi. 1989 Dec;52(8):1279-86 [2698043.001]
  • [Cites] Jpn J Med. 1990 Jul-Aug;29(4):379-83 [2273621.001]
  • [Cites] Semin Oncol. 1984 Dec;11(4):362-9 [6594759.001]
  • [Cites] Leuk Lymphoma. 1993;11 Suppl 2:109-14 [7907251.001]
  • [Cites] Jpn J Clin Oncol. 1997 Jun;27(3):146-53 [9255268.001]
  • [Cites] Blood. 1992 Feb 15;79(4):888-94 [1346578.001]
  • [Cites] Int J Hematol. 2004 Oct;80(3):267-77 [15540903.001]
  • [Cites] Mol Pharmacol. 2004 Jan;65(1):227-34 [14722255.001]
  • [Cites] Leukemia. 1995 Jan;9(1):25-9 [7845025.001]
  • [Cites] Blood. 1990 Jul 1;76(1):157-62 [2364167.001]
  • [Cites] Jpn J Clin Oncol. 1983 Sep;13(3):497-509 [6645081.001]
  • (PMID = 16207596.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 47M74X9YT5 / Cladribine
  •  go-up   go-down


18. Fujita H, Koharazawa H, Nishida H, Terada S, Morishita T, Kuroyama Y, Ohata M, Ishigatsubo Y: [Successful treatment of hairy cell leukemia with pentostatin]. Rinsho Ketsueki; 2001 Jul;42(7):537-42
Hazardous Substances Data Bank. PENTOSTATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Successful treatment of hairy cell leukemia with pentostatin].
  • Laboratory data showed a white blood cell count of 5,050/microliter with 78% abnormal lymphocytes, hemoglobin 6.8 g/dl, platelets 4.8 x 10(4)/microliter, and soluble IL-2 receptor 97,600/ml.
  • The abnormal cells were characterized by a hairy appearance under phase contrast microscopy, and showed strong tartrate-resistant acid phosphatase activity.
  • Bone marrow biopsy showed diffuse proliferation of hairy cells with moderate myelofibrosis.
  • We diagnosed the patient as having European-American-type hairy cell leukemia.
  • After twelve doses, the peripheral blood data returned to the normal range with no hairy cells in the blood or bone marrow, although slight splenomegaly remained.
  • The patient underwent splenectomy in December of the same year, and we were unable to find any hairy cells by histological and immunohistochemical examination.
  • Although most patients with hairy cell leukemia in Japan have the Japanese variant, and the European-American type is rare, pentostatin is as effective as it is for European and American patients.
  • [MeSH-major] Leukemia, Hairy Cell / drug therapy. Pentostatin / administration & dosage
  • [MeSH-minor] Female. Humans. Lymphocytes / pathology. Middle Aged. Receptors, Interleukin-2 / blood. Splenectomy. Treatment Outcome

  • Genetic Alliance. consumer health - Hairy Cell Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11524843.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Receptors, Interleukin-2; 395575MZO7 / Pentostatin
  •  go-up   go-down


19. Grever MR, Doan CA, Kraut EH: Pentostatin in the treatment of hairy-cell leukemia. Best Pract Res Clin Haematol; 2003 Mar;16(1):91-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pentostatin in the treatment of hairy-cell leukemia.
  • Pentostatin (2'-deoxycoformycin; Nipent), a potent inhibitor of adenosine deaminase, is a purine nucleoside analogue that is highly effective in the treatment of hairy-cell leukemia.
  • Long-term follow-up studies suggest that patients with hairy-cell leukemia who are induced into complete remission have a projected survival comparable to age-matched controls.
  • While purine nucleoside analogues induce profound T-cell dysfunction and longstanding immunosuppression, the incidence of secondary malignancies is apparently not increased.
  • Patients with this disease should be encouraged to participate in ongoing clinical trials to better define the optimal treatment regimen.
  • New studies should explore the combination of pentostatin and rituxan in treating the typical form of hairy-cell leukemia, and the incorporation of new agents for those with the rare variant form of this disease.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Antineoplastic Agents / therapeutic use. Enzyme Inhibitors / therapeutic use. Leukemia, Hairy Cell / drug therapy. Pentostatin / therapeutic use
  • [MeSH-minor] Clinical Trials, Phase II as Topic / methods. Clinical Trials, Phase III as Topic / methods. Dose-Response Relationship, Drug. Follow-Up Studies. Humans

  • Genetic Alliance. consumer health - Hairy Cell Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PENTOSTATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12670468.001).
  • [ISSN] 1521-6926
  • [Journal-full-title] Best practice & research. Clinical haematology
  • [ISO-abbreviation] Best Pract Res Clin Haematol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 395575MZO7 / Pentostatin
  • [Number-of-references] 27
  •  go-up   go-down


20. Li B, Brown KV, Wenke JC, Guelcher SA: Sustained release of vancomycin from polyurethane scaffolds inhibits infection of bone wounds in a rat femoral segmental defect model. J Control Release; 2010 Aug 3;145(3):221-30
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Considering that tissue regeneration is associated with new blood vessel formation, which takes up to 6 weeks in segmental defects, a biodegradable bone graft with sustained release of an antibiotic is desired to prevent the implant from becoming infected, thus allowing the processes of both vascularization and new bone formation to occur unimpeded.
  • Hydrophobic vancomycin free base (V-FB) was obtained by precipitating the hydrophilic vancomycin hydrochloride (V-HCl) at pH 8.
  • The decreased solubility of V-FB resulted in an extended vancomycin release profile in vitro, as evidenced by the fact that active vancomycin was released for up to 8 weeks at concentrations well above both the minimum inhibitory concentration (MIC) and the minimum bactericidal concentration (MBC).
  • Using PUR prepared from lysine triisocyanate (LTI) (PUR(LTI)), the extended in vitro release profile observed for V-FB translated to improved infection control in vivo compared to V-HCl in a contaminated critical-sized fat femoral segmental defect.
  • The performance of PUR(LTI)/V-FB was comparable to PMMA/V-HCl beads in vivo.
  • These results suggest that PUR scaffolds incorporating V-FB could be a potential clinical therapy for treatment of infected bone defects.
  • [MeSH-major] Anti-Bacterial Agents / administration & dosage. Anti-Bacterial Agents / therapeutic use. Delayed-Action Preparations / chemistry. Femur / drug effects. Polyurethanes / chemistry. Vancomycin / administration & dosage. Vancomycin / therapeutic use. Wound Infection / drug therapy

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Vancomycin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20382191.001).
  • [ISSN] 1873-4995
  • [Journal-full-title] Journal of controlled release : official journal of the Controlled Release Society
  • [ISO-abbreviation] J Control Release
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Delayed-Action Preparations; 0 / Polyurethanes; 6Q205EH1VU / Vancomycin
  •  go-up   go-down






Advertisement